The construct validity and responsiveness of the EQ-5D-5L, AQL-5D and a bespoke TTO in acute asthmatics

Abstract

Purpose Measuring quality of life in acute asthmatics is challenging, especially when asthma attacks can occur sporadically. Several questionnaires can be used to measure quality of life in this patient group; however, psychometric testing is limited on questionnaires that can be used to estimate Quality Adjusted Life years. The objective of this study is to assess the construct validity (convergent and discriminative validity) and responsiveness of the EuroQol-5-Dimensions 5-Level (EQ-5D-5L), Asthma Quality of Life Utility Index-5 Dimensions (AQL-5D) and Time Trade-Off (TTO) in acute asthma patients. Methods Data from a prospective cohort study were used to test the validity and responsiveness of the EQ-5D-5L, AQL-5D and TTO in asthma patients who were recruited from UK accident & emergency departments or hospital wards. The spearman's rank correlation coefficient, the Kruskal-Wallis test statistic and the standardized response mean were used to test for convergent validity, discriminative validity and responsiveness, respectively. Results One hundred and twenty-one participants were included in the available case analysis. The EQ-5D-5L and AQL-5D showed moderate to strong correlations for convergent validity at baseline, week 4 and week 8. The AQL-5D and TTO showed moderate correlations at week 4 and week 8. No statistical significance was observed for discriminative validity at baseline. Both the EQ-5D-5L and the AQL-5D also showed that they were sensitive to change for the recovery responses. Conclusions The EQ-5D-5L and AQL-5D showed stronger construct validity and responsiveness compared to the TTO. Therefore, both the EQ-5D-5L and AQL-5D should be considered for use in future economic evaluations.

Responsiveness and minimal clinically important difference of the EQ-5D-5L in cervical intraepithelial neoplasia: a longitudinal study

“…Responsiveness of the EQ-5D-5L in patients with improved health states was also studied in other populations; however, the results were inconsistent. In patients with acute asthma who underwent one month of treatment and self-reported improved health states, the index value had moderate to large responsiveness with the effect size ranged from 0.63 to 0.95 [50]. Golicki et al revealed that the EQ-5D-5L was consistently responsive in patients who had a stroke, who displayed improved health four months after treatment: the index value showed a moderate ES (0.51-0.71) and a moderate to large SRM (0.69-0.86), while the ES of EQ VAS ranged from 0.51 to 0.65 and the SRM ranged from 0.59 to 0.69 [51].…”

Responsiveness and minimal clinically important difference of the EQ-5D-5L in cervical intraepithelial neoplasia: a longitudinal study

“…Responsiveness of the EQ-5D-5L in patients with improved health states was also studied in other populations, but results were inconsistent. In acute asthmatics patients who underwent 1 month of treatment and self-reported improvement in health states, the UI had moderate to large responsiveness with effct size of 0.63 to 0.95 [40]. Golicki et al revealed that the EQ-5D-5L was consistently responsive in stroke patients with improved health 4 months after treatment, which UI showing moderate ES (0.51-0.71) and moderate to large SRM (0.69-0.86), and EQ VAS range from 0.51 to 0.65 for ES and 0.59 to 0.69 for SRM [41].…”

Responsiveness and minimal clinically important difference of the EQ-5D-5L in cervical intraepithelial neoplasia: a longitudinal study

“…Responsiveness of the EQ-5D-5L in patients with improved health states was also studied in other populations; however, the results were inconsistent. In patients with acute asthma, who underwent one month of treatment and self-reported improved health states, the index value had moderate to large responsiveness with the effect size ranged 0.63 to 0.95 [50]. Golicki and colleagues revealed that the EQ-5D-5L was consistently responsive in patients who had a stroke, who displayed improved health four months after treatment: the index value showed a moderate ES (0.51-0.71) and a moderate to large SRM (0.69-0.86), while the ES of EQ VAS ranged from 0.51 to 0.65 and the SRM ranged from 0.59 to 0.69 [51].…”